Mayne Pharma and Mithra announce TGA approval of Nextstellis® oral contraceptive

29 November 2021, 08:45, Adelaide, Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets). Mayne Pharma anticipates the commercial launch of NEXTSTELLIS by mid-2022 supported by healthcare professional market education from January 2022.

Liege, Belgium, November 29, 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the holding of its Investor Day today at its R&D and production center, the Mithra CDMO in Flémalle, Belgium.

As of 9:00 am CET, all presentations can be simultaneously followed by webcast on the Company’s website or by clicking here. A replay will also be available via this same link shortly after the end of the conference.

Information on the Total Number of Voting Rights Following the Completion of the LDA Capital Increase

Liege, Belgium, 10 November 2021 – 17:45 CET – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 314,162 new shares today for a total amount of EUR 5,727,177 following the Put Option Notice issued on July 2, 2021 in the framework of LDA capital.

Mithra organizes its Investor Day on November 29, 2021

Liege, Belgium, 10 November 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it will host an Investor Day on Monday, November 29, 2021 at 9:00 am CET.

The event will be broadcasted live via webcast, the link will be available soon on Mithra’s website.